Results 141 to 150 of about 7,683 (166)

Population-level and longitudinal MIC distributions for antimicrobials against drug-resistant <i>Mycobacterium tuberculosis</i> in Wuxi, a low-epidemic city in China, from 2019 to 2023. [PDF]

Front Cell Infect Microbiol
Gao S, Tu F, Ding H, Zhang Q, Zhang S, Shen S, Liu J, Xu Z.   +7 more
europepmc   +1 more source

Efficacy of Dolutegravir Plus Lamivudine in People With TB/HIV Co-Infection Using a Rifampicin or Rifabutin-Based Regimen: A Retrospective Observational Case Series. [PDF]

Immun Inflamm Dis
He J, He X, Xie X, Fu Y, Luo X, Peng Y, Xu B, Long H.   +7 more
europepmc   +1 more source

Indinavir and Rifabutin Drug Interactions in Healthy Volunteers [PDF]

Journal of Clinical Pharmacology, 2004
Two studies examined the pharmacokinetics of indinavir and rifabutin when coadministered in healthy subjects. Rifabutin, which induces the expression of cytochrome P450 (CYP) 3A, and indinavir, which inhibits that enzyme system, are frequently ...
Scott A. Waldman, Walter K. Kraft, Howard E Greenberg   +2 more
exaly   +2 more sources

In-Vitro Activity of Rifabutin Against Rifampicin-Resistant Mycobacterium tuberculosis Isolates With Known rpoB Mutations

Clinical Microbiology and Infection, 2004
The relationship between resistance to rifampicin and rifabutin and genetic alterations in the rpoB gene of 41 rifampicin-resistant isolates of Mycobacterium tuberculosis was evaluated.
A Bilgic
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Synergistic Rifabutin and Colistin Reduce Emergence of Resistance When Treating Acinetobacter baumannii.

Antimicrobial Agents and Chemotherapy, 2021
Brian Luna, Phd, Jun Yan, Brad Spellberg
exaly